Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 23, 2012

View Archived Issues

Gilead Sciences describes work on new dual beta2-adrenoceptor agonist/PDE4 inhibitors

Bristol-Myers Squibb reports discovery and first clinical data for new 11-beta-HSD1 inhibitor

FluCide drug candidates show oral efficacy in animal model

HTS hit-to-lead discovery program yields new GSK-3 beta inhibitors

Takeda presents new potent IAP inhibitors with promising oncolytic activity

ActoGeniX reports on phase I AG-013 trial

AstraZeneca updates progress of second quarter 2012

Prana provides update on Alzheimer's and Huntington's disease programs

Allergan and Molecular Partners expand collaboration

Collaboration yields novel potential analgesics

New agents for use in stem cell transplants disclosed

New TRPM8 channel antagonists disclosed by Dompe Farmaceutici

Bristol-Myers Squibb presents new beta-amyloid production inhibitors

Novel potential cognition-enhancing drugs designed

U.S. university develops new anticancer products

Novel candidate anticancer drugs synthesized in U.S.

Industry spotlight: Orphan drug R&D is a viable biopharma strategy

Kyowa Hakko Kirin launches pivotal mogamulizumab trial

AspenBio Pharma raises funds to develop AppyScore

Phase I trial of new TB vaccine candidate commences

Folate-rapamycin conjugate shows promise to treat PKD

EMA accepts MAA for Heplisav

Pluristem set to kick off phase II trial in intermittent claudication

Gevokizumab obtains orphan drug status for new indication

OXiGENE and Azanta expand Zybrestat agreement

U.K. authorities approve flutiform

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.